Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13891 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Philipp Badorrek und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany. Hauptthemen laut MEDLINE: Bronchiectasis, Cathepsin C, Healthy Volunteers. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Novel treatments are needed to reduce inflammation, improve symptoms, address exacerbations, and slow disease progression in bronchiectasis. Cathepsin C (CatC) inhibition promises to achieve this through reduction of neutrophil‐derived serine protease (including neutrophil elastase [NE] and proteinase 3 [PR3]) activation. Here, we present the phase I characterization of the novel CatC inhibitor, BI 1291583. Five phase I trials of BI 1291583 in healthy subjects are presented: a single‐rising‐dose study (NCT03414008) and two multiple‐rising‐dose studies (NCT03868540 and NCT04866160) assessing the safety, tolerability, pharmacodynamics, and pharmacokinetics of BI 1291583; a food effect study (NCT03837964); and a drug–drug interaction study (NCT03890887) of BI 1291583 and itraconazole. BI 1291583 was safe and well tolerated across the doses tested in these trials. Most adverse events (AEs) were mild or moderate in intensity, with no serious AEs, AEs of special interest or deaths reported in any trial. Drug‐related skin exfoliation was not reported more frequently in subjects treated with BI 1291583 compared with placebo. BI 1291583 was readily absorbed, and pharmacokinetics were supra‐proportional over the dose ranges assessed. Additionally, BI 1291583 inhibited CatC in a dose‐dependent manner, inhibited downstream NE activity, and decreased PR3 levels. No food effect was observed. Co‐administration of multiple doses of itraconazole increased BI 1291583 exposure approximately twofold. Due to these promising phase I results, a multinational phase II program of BI 1291583 in adults with bronchiectasis is ongoing (Airleaf™ [NCT05238675], Clairafly™ [NCT05865886], and Clairleaf™ [NCT05846230]).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
- Boehringer Ingelheim International GmbH, Ingelheim, Germany.
- Clinical Research Services, Mannheim, Germany.
- Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
- German Centre for Lung Research (DZL), Hannover, Germany.
ORCID-Profile: Friedeborg Seitz, Jens M Hohlfeld
Zitieren
APA
Badorrek, P., Diefenbach, C., Kögler, H., Eleftheraki, A., Seitz, F., & Hohlfeld, J. M. (2024). Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers. Clinical and Translational Science. https://doi.org/10.1111/cts.13891
Vancouver
Badorrek P, Diefenbach C, Kögler H, Eleftheraki A, Seitz F, Hohlfeld JM. Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers. Clinical and Translational Science. 2024. doi:10.1111/cts.13891
BibTeX
@article{Badorrek2024,
author = {Badorrek, Philipp and Diefenbach, Claudia and Kögler, Harald and Eleftheraki, Anastasia and Seitz, Friedeborg and Hohlfeld, Jens M},
title = {Novel cathepsin C inhibitor, BI 1291583, intended for treatment of bronchiectasis: Phase I characterization in healthy volunteers},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13891}
}
EUVIMED